Risk Screening & Primary Prevention of Elder Abuse in People Living With Dementia (WECARE)

February 19, 2026 updated by: University of Southern California

The goal of this clinical trial is to test a risk assessment screening and intervention for caregivers of people with dementia. The main questions it aims to answer are:

  1. What are the harms and benefits of administering the elder abuse risk assessment screening?
  2. What are the harms and benefits of administering the caregiver intervention?

Researchers will compare participants who receive the screening and caregiver intervention to a group who does not receive the caregiver intervention and a group who receives neither the screening or the caregiver intervention to answer these questions.

Participants will:

  • Complete two surveys, three months apart
  • Complete a 5-item screening tool, if assigned to one of the screening groups
  • Complete a 3-session caregiver intervention, if assigned to that group

Study Overview

Detailed Description

This study aims to address the issue of elder mistreatment which affects one in ten older adults, and is particularly prevalent among those with dementia, where rates can reach 50%. In this randomized study, caregivers are assigned to different study groups so researchers can evaluate outcomes across varying levels of support. The project examines how structured assessment and caregiver-focused education influence caregiver stress, decision-making, and overall care dynamics, with the broader aim of informing scalable prevention strategies within primary care systems

Study Type

Interventional

Enrollment (Estimated)

1000

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Los Angeles, California, United States, 90003
        • Keck Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18 years old or older
  • Speak English or Spanish
  • Caregiver for a person with Alzheimer's Disease or another type of dementia
  • Provide substantial care for this person, defined as assisting with at least one activity of daily living or two instrumental activities of daily living
  • See this person at least twice a week
  • Have access to the internet

Exclusion Criteria:

  • Under 18 years old
  • Speak language besides English or Spanish
  • Caregiver for person who does not have dementia
  • Do not provide substantial care for this person
  • Primary relationship between caregiver and person with dementia is that of a professional paid caregiver
  • Enrolled in another caregiver study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: Control
Participants will receive no intervention, only the two study surveys.
Experimental: Risk Assessment Screening Only
Participants will complete the risk assessment screening along with the two study surveys.
A five question tool that can be delivered verbally or through written self-administration.
Experimental: Risk Assessment Screening and Coach Intervention
Participants will complete the risk assessment screening, three coach sessions, intervention website, and the two study surveys.
A five question tool that can be delivered verbally or through written self-administration.
A three-session community health worker intervention, including a caregiver information website.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Caregiver Depression Symptoms
Time Frame: Enrollment to three months
Measured through Patient Health Questionnaire-8 score (0-24) .
Enrollment to three months
Caregiver Anxiety Symptoms
Time Frame: Enrollment to three months
Measured by Generalized Anxiety Disorder-7 screening tool score (0-21) .
Enrollment to three months
Caregiver Burden
Time Frame: Enrollment to three months
Measured by Zarit Burden Interview-6 scores (6-24)
Enrollment to three months
Caregiver Stress About Care Receiver Behavioral Symptoms
Time Frame: Enrollment to three months
Measured by Neuropsychiatric Inventory Questionnaire scores (0-60)
Enrollment to three months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Elder Mistreatment
Time Frame: Enrollment to three months
Measured using combined and modified Geriatric Mistreatment Scale and Older Adult Conflict Scale (0-19)
Enrollment to three months
Healthcare Use of Person Living with Demenita
Time Frame: Enrollment to three months
Count of each emergency department, hospitalization, and outpatient medical visits.
Enrollment to three months
Dementia Knowledge
Time Frame: Enrollment to three months
Measured using Dementia Attitudes Scale scores (0-36)
Enrollment to three months
Caregiver Self Efficacy
Time Frame: Enrollment to three months
Measured using Self-Efficacy for Caregiving scores (8-40)
Enrollment to three months
Resilience
Time Frame: Enrollment to three months
Measured using modified Brief Resilience Scale scores (6-24)
Enrollment to three months
Elder Abuse Knowledge
Time Frame: Enrollment to three months
Measured using survey questions from previous UK study, with summary scores ranging from 15 to 75 (higher numbers indicating higher understanding of elder abuse).
Enrollment to three months
Stress
Time Frame: Enrollment to three months
Measured using the Perceived Stress Scale scores (0-40)
Enrollment to three months
Emotional Regulation
Time Frame: Enrollment to three months
Measured using modified Difficulties in Emotion Regulation Scale (4-16)
Enrollment to three months
Anger
Time Frame: Enrollment to three months
Measured using the Dimensions of Anger Reactions scale (5-25)
Enrollment to three months
Hopelessness
Time Frame: Enrollment to three months
Measured using modified Beck Hopelessness Inventory scores (7-28)
Enrollment to three months
Social Support
Time Frame: Enrollment to three months
Measured using Duke/UNC Functional Social Support Questionnaire scores (8-40)
Enrollment to three months
Coping
Time Frame: Enrollment to three months
Measured using count of adaptive (0-18) and maladaptive (0-4) coping methods on novel measure
Enrollment to three months
Positive Aspects of Caregiving
Time Frame: Enrollment to three months
Measured using Positive Aspects of Caregiving Scale scores (6-24)
Enrollment to three months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Bonnie Olsen, PhD, University of Southern California
  • Principal Investigator: Laura Mosqueda, MD, University of Southern California

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

August 30, 2027

Study Registration Dates

First Submitted

February 4, 2026

First Submitted That Met QC Criteria

February 19, 2026

First Posted (Actual)

February 24, 2026

Study Record Updates

Last Update Posted (Actual)

February 24, 2026

Last Update Submitted That Met QC Criteria

February 19, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • R33AG078475 (U.S. NIH Grant/Contract)
  • 4R33AG078475-03 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Elder Abuse

Clinical Trials on Risk Assessment Screening

Subscribe